{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:06:05Z","timestamp":1776125165214,"version":"3.50.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ucl.2021.12.005","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T20:52:27Z","timestamp":1649796747000},"page":"249-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Medical Treatment of Overactive Bladder"],"prefix":"10.1016","volume":"49","author":[{"given":"Justin","family":"Loloi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitney","family":"Clearwater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia O.","family":"Suadicani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitya","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ucl.2021.12.005_bib1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1517\/14656566.2011.554396","article-title":"Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder","volume":"12","author":"Latini","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000447205","article-title":"Overactive Bladder Syndrome: Evaluation and Management","volume":"11","author":"Leron","year":"2018","journal-title":"Curr Urol"},{"key":"10.1016\/j.ucl.2021.12.005_bib3","first-page":"71","article-title":"Review of the epidemiology of overactive bladder","volume":"8","author":"Eapen","year":"2016","journal-title":"Res Rep Urol"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2021.12.005_bib4","first-page":"2","article-title":"Gender differences in overactive bladder","volume":"23","author":"Eapen","year":"2016","journal-title":"Can J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/SPV.0000000000000531","article-title":"Associations Between Risk Factors and Overactive Bladder: A Meta-analysis","volume":"25","author":"Zhu","year":"2019","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"11","key":"10.1016\/j.ucl.2021.12.005_bib6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1464-410X.2008.07573.x","article-title":"Understanding the elements of overactive bladder: questions raised by the EPIC study","volume":"101","author":"Irwin","year":"2008","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.005_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2021.12.005_bib8","first-page":"1","article-title":"Benign prostatic hyperplasia: epidemiology, economics and evaluation","volume":"22","author":"Vuichoud","year":"2015","journal-title":"Can J Urol"},{"key":"10.1016\/j.ucl.2021.12.005_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1757-5672.2011.00122.x","article-title":"Pathophysiology of overactive bladder","volume":"4","author":"Meng","year":"2012","journal-title":"LUTS: Lower Urinary Tract Symptoms"},{"issue":"3 Suppl 1","key":"10.1016\/j.ucl.2021.12.005_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.amjmed.2005.12.010","article-title":"Pathophysiology of overactive bladder","volume":"119","author":"Chu","year":"2006","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.005_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ajog.2016.01.156","article-title":"Nonantimuscarinic treatment for overactive bladder: a systematic review","volume":"215","author":"Olivera","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"3 Pt 2","key":"10.1016\/j.ucl.2021.12.005_bib12","first-page":"S5","article-title":"Overactive bladder: a better understanding of pathophysiology, diagnosis and management","volume":"175","author":"Wein","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"8","key":"10.1016\/j.ucl.2021.12.005_bib13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00192-012-1682-6","article-title":"Pathophysiology of overactive bladder","volume":"23","author":"Banakhar","year":"2012","journal-title":"Int Urogynecol J"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.005_bib14","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A\u00a0comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur Urol"},{"issue":"Suppl 4","key":"10.1016\/j.ucl.2021.12.005_bib15","first-page":"S7","article-title":"Pathophysiology of overactive bladder and urge urinary incontinence","volume":"4","author":"Steers","year":"2002","journal-title":"Rev Urol"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.005_bib16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11934-013-0353-6","article-title":"Understanding clinic options for overactive bladder","volume":"14","author":"Bartley","year":"2013","journal-title":"Curr Urol Rep"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib17","first-page":"337","article-title":"Pharmacologic management of overactive bladder","volume":"2","author":"Lam","year":"2007","journal-title":"Clin Interv Aging"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/13697137.2018.1552254","article-title":"Managing overactive bladder","volume":"22","author":"Robinson","year":"2019","journal-title":"Climacteric"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.005_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1755-5949.2011.00248.x","article-title":"Anticholinergics for overactive bladder therapy: central nervous system effects","volume":"18","author":"Chancellor","year":"2012","journal-title":"CNS Neurosci Ther"},{"issue":"7394","key":"10.1016\/j.ucl.2021.12.005_bib20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.326.7394.841","article-title":"Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review","volume":"326","author":"Herbison","year":"2003","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.005_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/PL00007103","article-title":"Oxybutynin and the overactive bladder","volume":"19","author":"Andersson","year":"2001","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.005_bib22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00192-012-1915-8","article-title":"Oxybutynin: past, present, and future","volume":"24","author":"Jirschele","year":"2013","journal-title":"Int Urogynecol J"},{"issue":"10","key":"10.1016\/j.ucl.2021.12.005_bib23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2165\/00019053-200523100-00003","article-title":"Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations","volume":"23","author":"Getsios","year":"2005","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.005_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.ucl.2021.12.005_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2165\/00044011-200626100-00007","article-title":"Psychotic disorder induced by oxybutynin: Presentation of two cases","volume":"26","author":"Gulsun","year":"2006","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.005_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/nau.24536","article-title":"Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta-analysis","volume":"40","author":"Dmochowski","year":"2021","journal-title":"Neurourology and urodynamics"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ucl.2021.12.005_bib28","doi-asserted-by":"crossref","first-page":"k1315","DOI":"10.1136\/bmj.k1315","article-title":"Anticholinergic drugs and risk of dementia: case-control study","volume":"361","author":"Richardson","year":"2018","journal-title":"Bmj"},{"issue":"8","key":"10.1016\/j.ucl.2021.12.005_bib29","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.005_bib30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bju.15040","article-title":"Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study","volume":"126","author":"Welk","year":"2020","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"issue":"2\u20133","key":"10.1016\/j.ucl.2021.12.005_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(97)89661-6","article-title":"Tolterodine--a new bladder-selective antimuscarinic agent","volume":"327","author":"Nilvebrant","year":"1997","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1016\/j.ucl.2021.12.005_bib33","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMra032662","article-title":"Management of overactive bladder","volume":"350","author":"Ouslander","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"3 Pt 1","key":"10.1016\/j.ucl.2021.12.005_bib34","first-page":"999","article-title":"Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction","volume":"175","author":"Abrams","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"19 Suppl","key":"10.1016\/j.ucl.2021.12.005_bib35","first-page":"S608","article-title":"Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder","volume":"8","author":"Kelleher","year":"2002","journal-title":"Am J Manag Care"},{"issue":"9","key":"10.1016\/j.ucl.2021.12.005_bib36","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1464-410X.2008.07939.x","article-title":"Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial","volume":"102","author":"Cardozo","year":"2008","journal-title":"BJU Int"},{"issue":"9","key":"10.1016\/j.ucl.2021.12.005_bib37","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.clinthera.2006.09.017","article-title":"Solifenacin succinate for the treatment of symptoms of overactive bladder","volume":"28","author":"Maniscalco","year":"2006","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.ucl.2021.12.005_bib38","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1742-1241.2006.01067.x","article-title":"Solifenacin significantly improves all symptoms of overactive bladder syndrome","volume":"60","author":"Chapple","year":"2006","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A\u00a0comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2021.12.005_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1464-410X.2005.05651.x","article-title":"Role of muscarinic receptor antagonists in urgency and nocturia","volume":"96","author":"Michel","year":"2005","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.005_bib41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjopharm.2006.03.004","article-title":"Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis","volume":"4","author":"Wagg","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.ucl.2021.12.005_bib42","first-page":"555","article-title":"Darifenacin\u2014a novel bladder-selective agent for the treatment of urge incontinence","volume":"14","author":"Newgreen","year":"1995","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.005_bib43","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1464-410X.2006.06439.x","article-title":"Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study","volume":"98","author":"Haab","year":"2006","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.eururo.2005.05.009","article-title":"Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist","volume":"48","author":"Foote","year":"2005","journal-title":"Eur Urol"},{"issue":"21","key":"10.1016\/j.ucl.2021.12.005_bib45","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2165\/00003495-200464210-00005","article-title":"Trospium chloride in the management of overactive bladder","volume":"64","author":"Rovner","year":"2004","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.005_bib46","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11934-003-0023-1","article-title":"Trospium chloride: a quaternary amine with unique pharmacologic properties","volume":"4","author":"Pak","year":"2003","journal-title":"Curr Urol Rep"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.005_bib47","first-page":"456","article-title":"Responses of isolated normal human detrusor muscle to various spasmolytic drugs commonly used in the treatment of the overactive bladder","volume":"50","author":"Uckert","year":"2000","journal-title":"Arzneimittelforschung"},{"issue":"6 Pt 1","key":"10.1016\/j.ucl.2021.12.005_bib48","first-page":"2311","article-title":"Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial","volume":"171","author":"Zinner","year":"2004","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.005_bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.urology.2005.08.017","article-title":"Multicenter phase III trial studying trospium chloride in patients with overactive bladder","volume":"67","author":"Rudy","year":"2006","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.005_bib50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11934-004-0064-0","article-title":"Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder","volume":"5","author":"Staskin","year":"2004","journal-title":"Curr Urol Rep"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.005_bib51","first-page":"2488","article-title":"Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome","volume":"178","author":"Nitti","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.005_bib52","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.urology.2010.03.097","article-title":"Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder","volume":"76","author":"Kraus","year":"2010","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.005_bib53","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.urology.2007.12.017","article-title":"Fesoterodine dose response in subjects with overactive bladder syndrome","volume":"71","author":"Khullar","year":"2008","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.005_bib54","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","article-title":"Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder","volume":"52","author":"Chapple","year":"2007","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ucl.2021.12.005_bib55","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14656566.9.10.1787","article-title":"Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome","volume":"9","author":"Michel","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.005_bib56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1464-410X.2009.09086.x","article-title":"Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial","volume":"105","author":"Herschorn","year":"2010","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.005_bib57","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.urology.2009.09.018","article-title":"Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder","volume":"75","author":"Dmochowski","year":"2010","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.005_bib58","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1742-1241.2009.02035.x","article-title":"Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study","volume":"63","author":"Wyndaele","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.005_bib59","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","article-title":"Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder","volume":"45","author":"Haab","year":"2004","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.005_bib60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/SPV.0000000000001008","article-title":"Clinical consensus statement: association of anticholinergic medication use and cognition in women with overactive bladder","volume":"27","author":"American Urogynecologic Society Guidelines Committee","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.005_bib61","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s11255-013-0621-x","article-title":"Association of inflammaging (inflammation\u00a0+ aging) with higher prevalence of OAB in elderly population","volume":"46","author":"Tyagi","year":"2014","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib62","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/jgs.14034","article-title":"Anticholinergic Drug Burden in Persons with Dementia Taking a Cholinesterase Inhibitor: The Effect of Multiple Physicians","volume":"64","author":"Reppas-Rindlisbacher","year":"2016","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib63","first-page":"558","article-title":"Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA\/SUFU Guideline Amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib64","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0022-3565(24)38094-2","article-title":"Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods","volume":"288","author":"Takeda","year":"1999","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib65","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.bjp.0702358","article-title":"Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle","volume":"126","author":"Igawa","year":"1999","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.ucl.2021.12.005_bib66","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/ijcp.12194","article-title":"Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies","volume":"67","author":"Nitti","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib67","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/AOG.0000000000004279","article-title":"Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options","volume":"137","author":"Escobar","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib68","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/iju.13498","article-title":"Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms\/overactive bladder: Comparison with placebo and tolterodine","volume":"25","author":"Sebastianelli","year":"2018","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.005_bib69","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11255-013-0509-9","article-title":"The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials","volume":"46","author":"Cui","year":"2014","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.005_bib70","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b2(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.005_bib71","first-page":"316","article-title":"International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR","volume":"204","author":"Staskin","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.005_bib72","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","article-title":"Discovery of Vibegron: A Potent and Selective \u03b23 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder","volume":"59","author":"Edmondson","year":"2016","journal-title":"J\u00a0Med Chem"},{"issue":"9","key":"10.1016\/j.ucl.2021.12.005_bib73","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s11255-015-1054-5","article-title":"Assessment of overactive bladder in women antidepressant users","volume":"47","author":"Albayrak","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ucl.2021.12.005_bib74","first-page":"1","article-title":"Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life","volume":"6","author":"Jayarajan","year":"2013","journal-title":"Res Rep Urol"},{"issue":"6 Pt 2","key":"10.1016\/j.ucl.2021.12.005_bib75","first-page":"2607","article-title":"Imipramine for therapy resistant enuresis: a retrospective evaluation","volume":"171","author":"Gepertz","year":"2004","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.005_bib76","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults","volume":"67","year":"2019","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.005_bib77","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0269881107088441","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines","volume":"22","author":"Anderson","year":"2008","journal-title":"J\u00a0Psychopharmacol"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib78","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.clpt.2003.09.019","article-title":"Cyclic antidepressants and the risk of sudden cardiac death","volume":"75","author":"Ray","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.005_bib79","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0022-3565(25)10548-X","article-title":"Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat","volume":"274","author":"Thor","year":"1995","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.ucl.2021.12.005_bib80","doi-asserted-by":"crossref","first-page":"172842","DOI":"10.1016\/j.pbb.2019.172842","article-title":"Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways","volume":"189","author":"Wr\u00f3bel","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.005_bib81","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1464-410X.2007.06980.x","article-title":"Duloxetine compared with placebo for treating women with symptoms of overactive bladder","volume":"100","author":"Steers","year":"2007","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.005_bib82","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/WNF.0b013e3182613dce","article-title":"Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a pilot study","volume":"35","author":"Di Rezze","year":"2012","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"10.1016\/j.ucl.2021.12.005_bib83","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/nau.22851","article-title":"Linking the evidence between urinary retention and antipsychotic or antidepressant drugs: A systematic review","volume":"35","author":"Faure Walker","year":"2016","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.005_bib84","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/nau.20613","article-title":"Desmopressin, as a \"designer-drug,\" in the treatment of overactive bladder syndrome","volume":"28","author":"Hashim","year":"2009","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.005_bib85","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4111\/kju.2011.52.6.396","article-title":"Effect of desmopressin with anticholinergics in female patients with overactive bladder","volume":"52","author":"Han","year":"2011","journal-title":"Korean J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.005_bib86","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jpurol.2019.12.020","article-title":"Management and treatment of nocturnal enuresis-an updated standardization document from the International Children's Continence Society","volume":"16","author":"Nev\u00e9us","year":"2020","journal-title":"J\u00a0Pediatr Urol"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib87","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bju.14539","article-title":"Comparison of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agents in the management of paediatric monosymptomatic nocturnal enuresis: a network meta-analysis","volume":"123","author":"Song","year":"2019","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.005_bib88","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11884-019-00562-3","article-title":"Advances in pharmacotherapy for the treatment of overactive bladder","volume":"14","author":"Painter","year":"2019","journal-title":"Curr Bladder Dysfunct Rep"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.005_bib89","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00192-020-04329-x","article-title":"Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?","volume":"32","author":"Wu","year":"2021","journal-title":"Int Urogynecol J"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.005_bib90","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ijcp.12540","article-title":"The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study","volume":"69","author":"Song","year":"2015","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib91","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1517\/13543784.2015.1001836","article-title":"Solabegron: a potential future addition to the \u03b2-3 adrenoceptor agonist armamentarium for the management of overactive bladder","volume":"24","author":"Ellsworth","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.005_bib92","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2012.05.053","article-title":"A\u00a0multicenter, double-blind, randomized, placebo-controlled trial of the \u03b23-adrenoceptor agonist solabegron for overactive bladder","volume":"62","author":"Ohlstein","year":"2012","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ucl.2021.12.005_bib93","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/nau.24158","article-title":"Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature","volume":"38","author":"Kasman","year":"2019","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.005_bib94","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.005_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000339251","article-title":"Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity","volume":"89","author":"Cerruto","year":"2012","journal-title":"Urol Int"},{"issue":"Suppl 3","key":"10.1016\/j.ucl.2021.12.005_bib96","article-title":"New targets for overactive bladder-ICI-RS 2109","volume":"39","author":"Fry","year":"2020","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.005_bib97","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrurol.2016.13","article-title":"Receptors, channels, and signalling in the urothelial sensory system in the bladder","volume":"13","author":"Merrill","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"8","key":"10.1016\/j.ucl.2021.12.005_bib98","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1442-2042.2008.02052.x","article-title":"Roles of mechanosensitive ion channels in bladder sensory transduction and overactive bladder","volume":"15","author":"Araki","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.ucl.2021.12.005_bib99","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/UROS.UROS_16_20","article-title":"Perspectives of medical treatment for overactive bladder","volume":"31","author":"Lin","year":"2020","journal-title":"Urol Sci"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014321019133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014321019133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:55:08Z","timestamp":1758808508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014321019133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0094014321019133"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2021.12.005","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Treatment of Overactive Bladder","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2021.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}